B细胞-话题@MedSci

#B细胞#

314篇内容 | 6683人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1273407, encodeId=9d7712e34072d, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=J Clin Invest：整合甲基化组-转录组分析揭示了婴儿MLL-重排型B细胞急性淋巴母细胞白血病的癌细胞脆弱性, objectType=article, longId=217332, objectId=283721e3323c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=283721e3323c, replyNumber=0, likeNumber=78, createdTime=2021-09-21, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=283721e3323c, moduleTitle=J Clin Invest：整合甲基化组-转录组分析揭示了婴儿MLL-重排型B细胞急性淋巴母细胞白血病的癌细胞脆弱性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=283721e3323c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273406, encodeId=972512e3406c4, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Lancet Oncol：Tisagenlecleucel用于难治/复发性侵袭性B细胞淋巴瘤的长期临床预后, objectType=article, longId=217065, objectId=6c6c21e06592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c6c21e06592, replyNumber=0, likeNumber=87, createdTime=2021-09-15, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c6c21e06592, moduleTitle=Lancet Oncol：Tisagenlecleucel用于难治/复发性侵袭性B细胞淋巴瘤的长期临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c6c21e06592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273405, encodeId=25ac12e3405f7, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Lancet：CD3/CD20双抗Epcoritamab，复发性/难治性B细胞非霍奇金淋巴瘤的新选择！, objectType=article, longId=216944, objectId=046e21694492, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=046e21694492, replyNumber=0, likeNumber=86, createdTime=2021-09-12, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=046e21694492, moduleTitle=Lancet：CD3/CD20双抗Epcoritamab，复发性/难治性B细胞非霍奇金淋巴瘤的新选择！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=046e21694492)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273404, encodeId=972212e340460, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Stroke：急性脑卒中后，胰岛B细胞功能如何影响预后?, objectType=article, longId=216048, objectId=fff921604856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fff921604856, replyNumber=0, likeNumber=97, createdTime=2021-08-21, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fff921604856, moduleTitle=Stroke：急性脑卒中后，胰岛B细胞功能如何影响预后?, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fff921604856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273403, encodeId=2e5a12e3403a6, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Clin Cancer Res：肿瘤浸润B细胞可预测采用达拉非尼+曲美替尼治疗的黑色素瘤患者的临床预后, objectType=article, longId=215840, objectId=dfc62158401b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfc62158401b, replyNumber=0, likeNumber=89, createdTime=2021-08-18, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfc62158401b, moduleTitle=Clin Cancer Res：肿瘤浸润B细胞可预测采用达拉非尼+曲美替尼治疗的黑色素瘤患者的临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfc62158401b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273402, encodeId=3b6e12e3402f5, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=iFLT-PET/CT是弥漫性大B细胞淋巴瘤化疗免疫治疗后无进展生存率的早期和优越预测指标, objectType=article, longId=215050, objectId=6c75215050c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c75215050c9, replyNumber=0, likeNumber=85, createdTime=2021-07-31, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c75215050c9, moduleTitle=iFLT-PET/CT是弥漫性大B细胞淋巴瘤化疗免疫治疗后无进展生存率的早期和优越预测指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c75215050c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273401, encodeId=42eb12e3401ea, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Nat Med：靶向CD19和CD22的双特异性CAR-T疗法可治疗复发性/难治性B细胞恶性肿瘤, objectType=article, longId=214948, objectId=920821494873, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=920821494873, replyNumber=0, likeNumber=71, createdTime=2021-07-29, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=920821494873, moduleTitle=Nat Med：靶向CD19和CD22的双特异性CAR-T疗法可治疗复发性/难治性B细胞恶性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=920821494873)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273400, encodeId=091112e3400f0, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验 , objectType=article, longId=214902, objectId=ef3021490202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef3021490202, replyNumber=0, likeNumber=60, createdTime=2021-07-29, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef3021490202, moduleTitle=Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef3021490202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273399, encodeId=778e12e33993e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：糖皮质激素对CAR-T细胞疗法治疗的大B细胞淋巴瘤患者预后的影响, objectType=article, longId=212729, objectId=d16b212e29ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d16b212e29ab, replyNumber=0, likeNumber=96, createdTime=2021-06-16, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d16b212e29ab, moduleTitle=Blood：糖皮质激素对CAR-T细胞疗法治疗的大B细胞淋巴瘤患者预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d16b212e29ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273398, encodeId=09ed12e3398f6, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Int J Clin Oncol：商品化 CAR T细胞治疗复发/难治性侵袭性B细胞淋巴瘤的疗效, objectType=article, longId=212401, objectId=f48f21240133, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f48f21240133, replyNumber=0, likeNumber=68, createdTime=2021-06-08, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f48f21240133, moduleTitle=Int J Clin Oncol：商品化 CAR T细胞治疗复发/难治性侵袭性B细胞淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f48f21240133)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273397, encodeId=5c1612e339795, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Br J Cancer：弥散性大B细胞淋巴瘤DLBCL的新型风险分层预测模型, objectType=article, longId=211832, objectId=fc31211832f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc31211832f6, replyNumber=0, likeNumber=83, createdTime=2021-05-27, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc31211832f6, moduleTitle=Br J Cancer：弥散性大B细胞淋巴瘤DLBCL的新型风险分层预测模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc31211832f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273396, encodeId=c67e12e339647, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=NEJM：抗B细胞成熟抗原CAR-T细胞疗法bb2121治疗多发性骨髓瘤的效果, objectType=article, longId=211106, objectId=51f721110637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51f721110637, replyNumber=0, likeNumber=81, createdTime=2021-05-12, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51f721110637, moduleTitle=NEJM：抗B细胞成熟抗原CAR-T细胞疗法bb2121治疗多发性骨髓瘤的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51f721110637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273395, encodeId=06f212e3395c2, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Clin Lymphoma Myeloma Leuk：CAR-T疗法可用于治疗异体造血干细胞移植后复发/难治的B细胞急淋白血病患者, objectType=article, longId=210737, objectId=56f3210e371b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56f3210e371b, replyNumber=0, likeNumber=78, createdTime=2021-05-03, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56f3210e371b, moduleTitle=Clin Lymphoma Myeloma Leuk：CAR-T疗法可用于治疗异体造血干细胞移植后复发/难治的B细胞急淋白血病患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56f3210e371b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273394, encodeId=87d712e33942d, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Science：新冠疫苗究竟管用多久？可能受年龄和组织中B细胞记忆的差异影响, objectType=article, longId=210613, objectId=3ae7210613fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ae7210613fe, replyNumber=0, likeNumber=116, createdTime=2021-04-30, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ae7210613fe, moduleTitle=Science：新冠疫苗究竟管用多久？可能受年龄和组织中B细胞记忆的差异影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ae7210613fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273393, encodeId=fd0a12e33933c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Nat Commun：耗竭B细胞可逆转阿尔茨海默病的进展, objectType=article, longId=210161, objectId=5e06210161dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e06210161dd, replyNumber=0, likeNumber=95, createdTime=2021-04-20, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e06210161dd, moduleTitle=Nat Commun：耗竭B细胞可逆转阿尔茨海默病的进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e06210161dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273392, encodeId=f62b12e339249, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=J Clin Oncol：新型双特异性抗体Glofitamab用于难治性侵袭性B细胞非霍奇金淋巴瘤的活性, objectType=article, longId=208782, objectId=0413208e8273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0413208e8273, replyNumber=0, likeNumber=106, createdTime=2021-03-22, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0413208e8273, moduleTitle=J Clin Oncol：新型双特异性抗体Glofitamab用于难治性侵袭性B细胞非霍奇金淋巴瘤的活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0413208e8273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273391, encodeId=a6d112e33910c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：血管内大B细胞淋巴瘤的遗传特征, objectType=article, longId=208781, objectId=48ff208e81d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48ff208e81d8, replyNumber=0, likeNumber=96, createdTime=2021-03-22, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48ff208e81d8, moduleTitle=Blood：血管内大B细胞淋巴瘤的遗传特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48ff208e81d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273389, encodeId=e0e812e338993, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=JAMA：Blinatumomab可提高首次复发的B细胞急性淋巴细胞白血病高危患儿无事件生存率, objectType=article, longId=207858, objectId=4adc20e8585b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4adc20e8585b, replyNumber=0, likeNumber=85, createdTime=2021-03-05, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4adc20e8585b, moduleTitle=JAMA：Blinatumomab可提高首次复发的B细胞急性淋巴细胞白血病高危患儿无事件生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4adc20e8585b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273388, encodeId=a65512e338803, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=JAMA：Blinatumomab vs 化疗用于首次复发的B细胞急性淋巴细胞白血病儿童、青少年和年轻患者, objectType=article, longId=207857, objectId=663420e857ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=663420e857ae, replyNumber=0, likeNumber=78, createdTime=2021-03-05, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=663420e857ae, moduleTitle=JAMA：Blinatumomab vs 化疗用于首次复发的B细胞急性淋巴细胞白血病儿童、青少年和年轻患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=663420e857ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273390, encodeId=b57e12e339010, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=J Immunother Cancer：纳米胶囊化的利妥昔单抗在具有补体活性的人源化小鼠模型中介导对转移性B细胞淋巴瘤的优异细胞免疫, objectType=article, longId=207605, objectId=7f8820e605f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f8820e605f3, replyNumber=0, likeNumber=132, createdTime=2021-02-27, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f8820e605f3, moduleTitle=J Immunother Cancer：纳米胶囊化的利妥昔单抗在具有补体活性的人源化小鼠模型中介导对转移性B细胞淋巴瘤的优异细胞免疫, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f8820e605f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

B细胞

2020-05-29

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

J Clin Invest：整合甲基化组-转录组分析揭示了婴儿MLL-重排型B细胞急性淋巴母细胞白血病的癌细胞脆弱性

2021-09-21

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Lancet Oncol：Tisagenlecleucel用于难治/复发性侵袭性B细胞淋巴瘤的长期临床预后

2021-09-15

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Lancet：CD3/CD20双抗Epcoritamab，复发性/难治性B细胞非霍奇金淋巴瘤的新选择！

2021-09-12

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Stroke：急性脑卒中后，胰岛B细胞功能如何影响预后?

2021-08-21

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Clin Cancer Res：肿瘤浸润B细胞可预测采用达拉非尼+曲美替尼治疗的黑色素瘤患者的临床预后

2021-08-18

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

iFLT-PET/CT是弥漫性大B细胞淋巴瘤化疗免疫治疗后无进展生存率的早期和优越预测指标

2021-07-31

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Nat Med：靶向CD19和CD22的双特异性CAR-T疗法可治疗复发性/难治性B细胞恶性肿瘤

2021-07-29

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验

2021-07-29

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：糖皮质激素对CAR-T细胞疗法治疗的大B细胞淋巴瘤患者预后的影响

2021-06-16

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Int J Clin Oncol：商品化 CAR T细胞治疗复发/难治性侵袭性B细胞淋巴瘤的疗效

2021-06-08

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Br J Cancer：弥散性大B细胞淋巴瘤DLBCL的新型风险分层预测模型

2021-05-27

智者为医08 (审核中...)

前往app查看评论内容

#B细胞#

NEJM：抗B细胞成熟抗原CAR-T细胞疗法bb2121治疗多发性骨髓瘤的效果

2021-05-12

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Clin Lymphoma Myeloma Leuk：CAR-T疗法可用于治疗异体造血干细胞移植后复发/难治的B细胞急淋白血病患者

2021-05-03

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Science：新冠疫苗究竟管用多久？可能受年龄和组织中B细胞记忆的差异影响

2021-04-30

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Nat Commun：耗竭B细胞可逆转阿尔茨海默病的进展

2021-04-20

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

J Clin Oncol：新型双特异性抗体Glofitamab用于难治性侵袭性B细胞非霍奇金淋巴瘤的活性

2021-03-22

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：血管内大B细胞淋巴瘤的遗传特征

2021-03-22

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

JAMA：Blinatumomab可提高首次复发的B细胞急性淋巴细胞白血病高危患儿无事件生存率

2021-03-05

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

JAMA：Blinatumomab vs 化疗用于首次复发的B细胞急性淋巴细胞白血病儿童、青少年和年轻患者

2021-03-05

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

J Immunother Cancer：纳米胶囊化的利妥昔单抗在具有补体活性的人源化小鼠模型中介导对转移性B细胞淋巴瘤的优异细胞免疫

2021-02-27

科室
- - 订阅+
  - 更多科室
工具
服务